Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron [MG]) combined with a supplement (alpha-lipoic acid [ALA]) may help.
Objective:
To learn how MG and ALA can help the body process food.
Eligibility:
People aged 18 to 65 years with a body mass index between 30 and 40 kg/m2.
Design:
Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.
The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.
During the clinic stays, participants will undergo many tests:
They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.
They will have imaging scans.
They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.
Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine.
They will log their diet, exercise, and sleep....

Start Date25 Dec 2024

Sponsor / Collaborator

National Institute of Diabetes & Digestive & Kidney Diseases

CTR20244008 / RecruitingNot Applicable

米拉贝隆缓释片在健康受试者中单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复空腹和餐后状态下的生物等效性试验

[Translation] A single-center, open-label, randomized, single-dose, two-formulation, two-sequence, four-cycle, fully repeated bioequivalence study of mirabegron extended-release tablets in healthy subjects under fasting and fed conditions

主要目的比较空腹和餐后给药条件下，浙江康恩贝制药股份有限公司生产的米拉贝隆缓释片（50mg）与Astellas Pharma Europe B.V.持证的米拉贝隆缓释片（50mg，商品名：贝坦利（BETMIGA））在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的评价空腹和餐后给药条件下，浙江康恩贝制药股份有限公司生产的米拉贝隆缓释片（50mg）与Astellas Pharma Europe B.V.持证的米拉贝隆缓释片（50mg，商品名：贝坦利（BETMIGA））在健康成年人群中的安全性。

[Translation]

Primary objective To compare the differences in the extent and rate of absorption of Mirabegron sustained-release tablets (50 mg) produced by Zhejiang Kangenbei Pharmaceutical Co., Ltd. and Mirabegron sustained-release tablets (50 mg, trade name: BETMIGA) licensed by Astellas Pharma Europe B.V. in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective To evaluate the safety of Mirabegron sustained-release tablets (50 mg) produced by Zhejiang Kangenbei Pharmaceutical Co., Ltd. and Mirabegron sustained-release tablets (50 mg, trade name: BETMIGA) licensed by Astellas Pharma Europe B.V. in healthy adults under fasting and postprandial administration conditions.

Start Date23 Nov 2024

Sponsor / Collaborator

Zhejiang Conba Pharmaceutical Co., Ltd.

NCT06534762 / RecruitingPhase 2IIT

Efficacy and Safety of Milaberon in Combination With Standard Therapy in Advanced Solid Tumors: an Open, Multicenter, Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical recommend dose of this product is 50mg/day, and the dose used in this study is 100mg/day, which is larger than the clinical commonly used dose. The main adverse reactions of this product are urinary tract infection and rapid heartbeat. In the clinical study, we will focus on the urine routine and heart-related adverse events of the subjects, and deal with the adverse events in time.
Subjects were given mirabeeron 100mg/day orally once a day in the morning until disease progression. When there are related or possible related side effects of the study drug mirabeeron, and according to NCI-CTCAE V 5.0, when subjects have more than or equal to grade 3 related toxicity, the administration should be delayed until grade 2 or lower to baseline, and the dose will be reduced by 50%, and subsequent dose increase is not allowed. If the pre-dose criteria are not met within 28 days, the drug will be permanently discontinued.

Start Date15 Jul 2024

Sponsor / Collaborator

Zhejiang Provincial Peoples Hospital

100 Clinical Results associated with Mirabegron

100 Translational Medicine associated with Mirabegron

100 Patents (Medical) associated with Mirabegron

868

Literatures (Medical) associated with Mirabegron

01 Jan 2025·LUTS-Lower Urinary Tract Symptoms

Comparison of the 3‐Year Continuation Rate and Discontinuation Factors Between Vibegron and Mirabegron in Patients With Overactive Bladder: A Retrospective Follow‐Up Study in a Rehabilitation Hospital in Japan

Article

Author: Nomi, Masashi ; Mukai, Shigeto ; Yanagiuchi, Akihiro ; Sengoku, Atsushi

ABSTRACT:

Objectives:

The objective of this study is to compare the 3‐year continuation rate and discontinuation factors between vibegron and mirabegron in patients with overactive bladder in a rehabilitation hospital in Japan.

Methods:

The 3‐year continuation rate of the target drugs and reasons for discontinuation as well as patients' backgrounds and adverse effects were evaluated retrospectively from the medical records between September 2018 and December 2020. After selecting patients according to our inclusion and exclusion criteria, 136 cases taking mirabegron and 82 taking vibegron were adjusted for intergroup variability by propensity score matching. We performed Cox proportional hazards regression for the 3‐year continuation rate and Fine‐Gray proportional hazards regression for the 3‐year cumulative incidence of discontinuation events. Subgroup analysis was also performed.

Results:

Approximately 70% of the patients analyzed had neurogenic overactive bladder. The 3‐year continuation rate was 65.2% in vibegron and 30.3% in mirabegron, and the hazard ratio was 0.41 (95% confidence interval: 0.25–0.68, p < 0.001) as for an incidence of discontinuation events of vibegron against mirabegron. The incidence of discontinuation due to inadequate efficacy was 22.7% in vibegron and 47.0% in mirabegron, and similarly the hazard ratio was 0.43 (95% confidence interval: 0.23–0.80, p < 0.01). In the subgroup analysis, vibegron continued significantly more than mirabegron for the 3‐year continuation rate in non‐neurogenic overactive bladder (p < 0.001), in spontaneous voiding (p < 0.001), in anticholinergic combination (p = 0.0017), in female (p < 0.001), and in 70 years or older (p = 0.0028). Additionally, a significant interaction was observed regarding the methods of emptying urine (p = 0.0066).

Conclusions:

Vibegron was superior to mirabegron in the 3‐year continuation rate of administration with a fewer discontinuation due to inadequate efficacy in a patient population with relatively high rates of neurogenic overactive bladder.

01 Dec 2024·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Computational insights into human UCP1 activators through molecular docking, MM-GBSA, and molecular dynamics simulation studies

Article

Author: Shukla, Ravi ; Paul, Atish T. ; Jagtap, Utkarsh A. ; Rathod, Sanket ; Jagtap, Utkarsh A ; Paul, Atish T

The prevalence of obesity is rapidly increasing worldwide. Brown adipose tissue activates uncoupling protein 1 (UCP1) to generate heat through bypassing ATP synthesis, offering a potential target for obesity treatment. Targeting UCP1 activation to induce thermogenesis through small molecules presents a promising approach for obesity management. In this study, molecular docking of UCP1 activators, using 2,4-dinitrophenol (DNP) as a reference ligand (PDB ID: 8J1N, docking score: -5.343 kcal/mol), identified seven top-scoring compounds: naringin (-7.284 kcal/mol), quercetin (-6.661 kcal/mol), salsalate (-6.017 kcal/mol), rhein (-5.798 kcal/mol), mirabegron (-5.535 kcal/mol), curcumin (-5.479 kcal/mol), and formoterol (-5.451 kcal/mol). Prime MM-GBSA calculation of the top-scored molecule (i.e., naringin) in the docking study showed ΔGBind of -70.48 kcal/mol. Key interactions of these top 7 activators with UCP1 binding pocket residues Trp280, Arg276, Glu190, Arg83, and Arg91 were observed. Molecular dynamics simulations performed for 100 ns confirmed complex stability, with RMSD values below 6 Å. Additionally, most activators showed favorable intestinal absorption (>90 %) and lipophilicity (LogP 2-4), with pKa values supporting their pharmacological potential as UCP1-targeting therapeutics for obesity. These findings provide a foundation for designing potent UCP1 activators by integrating docking scores, interaction profiles, statistical profiles from MD simulations, and physicochemical assessments to develop effective anti-obesity therapies.

01 Dec 2024·BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phenotypic characteristics of adipocyte-like cells generated from C2C12 myoblasts cultured with chicken serum

Article

Author: Ijiri, Daichi ; Katafuchi, Ayumi ; Kohrogi, Rukana ; Tomonaga, Shozo ; Shimamoto, Saki ; Nakamura, Kiriko ; Nakashima, Kazuki ; Ohtsuka, Akira

The aim of this study was to clarify the transcriptional and metabolic characteristics of C2C12 myoblasts cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 20 % chicken serum (CHS) (C2C12-CHS cells) compared with C2C12 myoblasts cultured in DMEM containing 20 % fetal bovine serum (FBS) (C2C12-FBS cells). After 3 days of culture, C2C12-CHS cells showed a marked accumulation of lipid droplets, accompanied by increased expression levels of brown adipocyte-related genes (i.e., Bmp7, Prdm16, Ucp1, Cidea, Pgc1α, Cox7a1, Cox8, and β₃-adorenoceptor). Furthermore, stimulation of β₃-adorenoceptor by its selective agonist, mirabegron, increased the mRNA expression of Ucp1 and Pgc1α in C2C12-CHS cells. Wide-targeted metabolomic analysis performed by gas chromatography-tandem mass spectrometry revealed that the metabolic profile of C2C12-CHS cells was obviously different to that of C2C12-FBS cells. Additionally, the metabolomic analysis indicated that β₃-adrenoceptor stimulation by mirabegron upregulated energy metabolism in C2C12-CHS cells as seen in brown adipocytes. These results suggest that C2C12-CHS cells may differentiate into brown adipocyte-like cells, accompanied by increased functional β₃-adrenoceptor.

News (Medical) associated with Mirabegron

04 Dec 2024

·www.drugs.com

Overactive Bladder Diagnoses Increased After Guideline Publication

WEDNESDAY, Dec. 4, 2024 -- An increase in overactive bladder (OAB) diagnoses was seen following publication of the first OAB guideline, and the rate of third-line therapy procedures also increased, according to a study published online Nov. 19 in Neurourology & Urodynamics . Hodan Mohamud, from the University of Toronto, and colleagues conducted a retrospective cohort study to examine trends in therapy utilization before and after the 2014 American Urological Association/Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction OAB guideline amendment and publication of a clinical care pathway in 2016. Patterns of care were assessed from 2013 to 2018. The study included 1,825,782 patients (mean age, 61.1 ± 16.7 years). From 2013 to 2017, the researchers found a 369 percent increase in the number of new OAB diagnoses. Nineteen percent of patients were treated with oral and/or third-line therapies during the six-year study period. The number of oral medications prescribed peaked in 2016, then decreased 17 percent by 2018. The two most prescribed oral medications in 2013 were oxybutynin and solifenacin (46.0 and 31.8 percent, respectively). Mirabegron surpassed solifenacin by 2018 (18.5 versus 16.5 percent), while oxybutynin still accounted for most prescriptions (55 percent). Patients older than 65 years of age filled 80 percent of all initial mirabegron prescriptions. From 2013 to 2018, the rate of third-line therapy procedures nearly doubled (nine to 17 per 1,000 OAB patients). "These trends suggest that OAB therapy guidelines and clinical practice pathways may influence treatment patterns," the authors write. One author disclosed ties to the pharmaceutical industry.

Clinical Result

02 Dec 2024

·www.prnewswire.com

Endo Launches ADRENALIN® Ready-to-Use Premixed Bag, the First and Only FDA-Approved, Manufacturer-Prepared Epinephrine Premixed IV Bag

MALVERN, Pa., Dec. 2, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of its ADRENALIN® (epinephrine in 0.9% sodium chloride injection) ready-to-use premixed bag, the first and only FDA-approved, manufacturer-prepared epinephrine premixed intravenous (IV) bag. "The first-ever ready-to-use epinephrine premixed bag represents an advancement for both providers and patients thanks to a delivery system that provides greater workflow efficiency, saves time, and reduces the risk of medication error," said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions & Generics. "We are proud to provide critical care products like ADRENALIN® bags—ready when and where our customers need them—through our TruDelivery® portfolio." The ADRENALIN® premixed bag is the latest addition to Endo Injectable Solutions' TruDelivery® product line and platform. Ready-to-use products streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow, and reduce the chance for preparation error—all of which support quality patient care. The ADRENALIN® premixed bag does not require compounding, diluting, mixing, or transferring, which may reduce waste. The single-port IV tubing reduces risk of inadvertently adding other medications to bag. The product also has a 24-month shelf life at room temperature. Endo also offers ADRENALIN® (epinephrine injection, USP) in 1 mL single-dose vials and 30 mL multi-dose vials. ADRENALIN® is used in the treatment of hypotension associated with septic shock. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Hypertension: Because individual response to epinephrine may vary significantly, monitor blood pressure frequently and titrate to avoid excessive increases in blood pressure. Patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may experience severe, prolonged hypertension when given epinephrine. Pulmonary Edema: Epinephrine increases cardiac output and causes peripheral vasoconstriction, which may result in pulmonary edema. Cardiac Arrhythmias and Ischemia: Epinephrine may induce cardiac arrhythmias and myocardial ischemia in patients, especially patients suffering from coronary artery disease, or cardiomyopathy. Extravasation and Tissue Necrosis with Intravenous Infusion: Avoid extravasation of epinephrine into the tissues, to prevent local necrosis. When Adrenalin is administered intravenously, check the infusion site frequently for free flow. Blanching along the course of the infused vein, sometimes without obvious extravasation, may be attributed to vasa vasorum constriction with increased permeability of the vein wall, permitting some leakage. This also may progress on rare occasions to superficial slough. Hence, if blanching occurs, consider changing the infusion site at intervals to allow the effects of local vasoconstriction to subside. There is potential for gangrene in a lower extremity when infusions of catecholamine are given in an ankle vein. Antidote for Extravasation Ischemia: To prevent sloughing and necrosis in areas in which extravasation has taken place, infiltrate the area with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of phentolamine, an adrenergic blocking agent. Use a syringe with a fine hypodermic needle, with the solution being infiltrated liberally throughout the area, which is easily identified by its cold, hard, and pallid appearance. Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours. Renal Impairment: Epinephrine constricts renal blood vessels, which may result in oliguria or renal impairment. ADVERSE REACTIONS: Most common adverse reactions to systemically administered epinephrine are headache; anxiety; apprehensiveness; restlessness; tremor; weakness; dizziness; sweating; palpitations; pallor; peripheral coldness; nausea/vomiting; and/or respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred. DRUG INTERACTIONS: Drugs that counter the pressor effects of epinephrine include alpha blockers, vasodilators such as nitrates, diuretics, antihypertensives, and ergot alkaloids. Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, catechol-O-methyltransferase (COMT) inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. Drugs that increase the arrhythmogenic potential of epinephrine include beta blockers, cyclopropane and halogenated hydrocarbon anesthetics, antihistamines, exogenous thyroid hormones, diuretics, cardiac glycosides, and quinidine. Observe for development of cardiac arrhythmias. Potassium-depleting drugs, including corticosteroids, diuretics, and theophylline, potentiate the hypokalemic effects of epinephrine. USE IN SPECIFIC POPULATIONS: Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally. INDICATION AND USAGE Hypotension associated with Septic Shock Adrenalin is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. Click for Full Prescribing Information. About Endo Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at or connect with us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements including, but not limited to, the statements by Mr. Sims and any statements relating to product launch, quality, efficacy, improved treatment, workflow efficiencies, reduced risks, waste or costs, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, regulatory compliance, unexpected litigation or disputes, Endo's ability to successfully implement and execute on its strategies and initiatives, and changes in competitive, market or regulatory conditions. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A. SOURCE Endo, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

15 Nov 2024

·www.adalvo.com

Adalvo Announces Successful EU Approval for Mirabegron 50mg Prolonged-Release Tablets

Adalvo secures successful DCP approval for Mirabegron 50mg prolonged-release tablets. Developed based on the reference brand Betmiga prolonged-release tablets, Mirabegron is indicated for the treatment of urgency, increased micturition frequency, and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. According to IQVIA, Mirabegron achieved approximately $3.3Bn in global sales in 2023, with a 3-year CAGR of 2%. Additionally, registrations for Mirabegron 25mg are currently ongoing, demonstrating Adalvo's commitment to providing a wide range of treatment options. Adalvo’s success in securing this approval reflects our capabilities to develop complex, differentiated products. Building on the success of Mirabegron, Adalvo is also progressing well with the development of Mirabegron+Solifenacin, further expanding our portfolio and enhancing treatment options for patients. There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. Partner Up Now! Click Here To Get In Touch! © 2022-2024 Adalvo Limited. All right reserved

Drug Approval

100 Deals associated with Mirabegron

External Link

KEGG	Wiki	ATC	Drug Bank
D09535	Mirabegron	G04BD12	DB08893

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neurogenic detrusor overactivity	EU	Astellas Pharma Europe Ltd.	05 Sep 2024
Neurogenic detrusor overactivity	IS	Astellas Pharma Europe Ltd.	05 Sep 2024
Neurogenic detrusor overactivity	LI	Astellas Pharma Europe Ltd.	05 Sep 2024
Neurogenic detrusor overactivity	NO	Astellas Pharma Europe Ltd.	05 Sep 2024
Overactive bladder syndrome	EU	Astellas Pharma Europe Ltd.	20 Dec 2012
Overactive bladder syndrome	IS	Astellas Pharma Europe Ltd.	20 Dec 2012
Overactive bladder syndrome	LI	Astellas Pharma Europe Ltd.	20 Dec 2012
Overactive bladder syndrome	NO	Astellas Pharma Europe Ltd.	20 Dec 2012
Urinary Bladder, Overactive	JP	Astellas Pharma, Inc.	01 Jul 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystitis, Interstitial	Phase 3	US	Astellas Pharma Global Development, Inc.	01 Aug 2016
Urinary Incontinence	Phase 3	US	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	AM	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	AU	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	AT	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	BE	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	CA	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	CZ	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	DK	Astellas Pharma Europe Ltd.	10 Jul 2013
Urinary Incontinence	Phase 3	FI	Astellas Pharma Europe Ltd.	10 Jul 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MIRAQL-BAT STUDY (EANM2024)	Not Applicable	-	20	Mirabegron 100 mg/day + Placebo	pgbbauqonl(qaivxmcpeq) = aglrjhehvp xpyxuomnxq (wtqfdtdghe ) View more	Positive	27 Sep 2024
				Mirabegron 200 mg/day + Placebo	pgbbauqonl(qaivxmcpeq) = ahniuyduje xpyxuomnxq (wtqfdtdghe ) View more
NCT04766021 (CTgov)	Phase 1/2	-	30	Placebo (Placebo)	qfptzdptcd(cuodypxzbm) = jiusyopkts omhdoyowpv (qxmtwwvsvt, kayxwkmpvq - wwellpesoo) View more	-	12 Jul 2024
				Mirabegron (100 mg Mirabegron)	qfptzdptcd(cuodypxzbm) = kgayozaowa omhdoyowpv (qxmtwwvsvt, iddpfrbpru - davhdfnzbm) View more
PD07-09 (AUA2024)	Not Applicable	-	-	Mirabegron	uypehkwbcm(eqaztfwssx) = cwelccyibc hrfjeprvfk (whlrvdjsvh )	Positive	01 May 2024
				Anticholinergics	uypehkwbcm(eqaztfwssx) = mupxxqkddu hrfjeprvfk (whlrvdjsvh )
NCT01876433 (Pubmed \| J Cardiovasc Pharmacol) Manual	Phase 2	Heart failure with reduced ejection fraction	57	Mirabegron (300 mg/day)	xjzhdujrmm(tvuisweghn) = Baseline and follow-up data: placebo: 13 ± 7 to 13 ± 5; mirabegron: 12 ± 6 to 13 ± 8 ujykgxdiya (hbfzdmhihx ) View more	Positive	05 Mar 2024
				Placebo
NCT04641975 (Dolphin, CTgov)	Phase 3	Urinary Bladder, Overactive	26	Mirabegron (Mirabegron (5 to < 12 Years))	ylqqthiujd(uobwqbjfil) = tcouxuwlyy apywwmkmrj (kiezfmjqdd, kcbfcgbjoc - dgivengeyr) View more	-	28 Dec 2023
				Placebo (Placebo (5 to < 12 Years))	ylqqthiujd(uobwqbjfil) = jnoazhonjl apywwmkmrj (kiezfmjqdd, zoffmxneik - ijveyqacmh) View more
NCT02599480 (Beta3-LVH, Pubmed \| JAMA Cardiol)	Phase 2	Heart Diseases	296	Mirabegron 50 mg/d	ujjccadlwd(ceqcwwbfao) = mbyjudobtk avyiavjvhu (nzxvphukzg, -0.15 to 2.74)	Negative	01 Nov 2023
NCT02086188 (MIRROR, CTgov)	Phase 4	Urinary urgency \| Multiple Sclerosis \| Urinary Bladder, Overactive	28	Mirabegron (Mirabegron)	shzsgrmskp(banambrzyw) = xznbnirqrc szgykuokty (ibjzwhxdbx, cbgjximtxk - tdopzclyhi) View more	-	18 Oct 2023
				Placebo (Placebo)	shzsgrmskp(banambrzyw) = cuaqumbkmw szgykuokty (ibjzwhxdbx, nsteryudvk - qezgbfxouv) View more
NCT02462837 (CTgov)	Phase 2	Pain \| Lower Urinary Tract Symptoms \| Urinary Bladder, Overactive	11	Mirabegron (Treatment Arm)	bxqxtyrhfu(qheryvjyoz) = irwqxskoue psnzoshpbu (bpqxktcjkc, vukyfesyxs - kjygaysedo) View more	-	13 Jun 2023
				Placebo (Placebo Arm)	bxqxtyrhfu(qheryvjyoz) = yhewzzdtoe psnzoshpbu (bpqxktcjkc, pjvlccutnp - wvufcnbnfv) View more
AUA2023	Not Applicable	Chronic prostatitis	-	Alpha blockers	dxwkcqlyxq(fbaohujfsy) = edkjeajnih tspqoolpjo (qvxuajhqlv )	-	01 Apr 2023
				Placebo	dxwkcqlyxq(fbaohujfsy) = gfvjlpnkmm tspqoolpjo (qvxuajhqlv )
PD14-07 (AUA2023)	Not Applicable	-	-	Mirabegron	giaaujtzpp(xvlzspdvml) = vzgoldgfdj rvljzofskq (cocewqajyn ) View more	-	01 Apr 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis